Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Trial of EirGenix Pertuzumab (EG1206A) vs Perjeta in Healthy Volunteers
NCT05471648Phase 1Completed
- Sponsor
- EirGenix
- Start
- May 2022
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pertuzumab in breast cancer (3 arms), sponsored by EirGenix. Primary endpoint: Area Under the Concentration-Time Curve From Time Zero to Infinity. Started May 2022; status: completed.
02
Drugs
pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05471648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05471648.